SBIR/STTR Research Award
Contract Award for SBIR Topic 061 ""Mucosal Stimulatory VesiVax Vaccines Against Enteric Infections""
Award amount
$213,800Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
This proposal aim to develop a liposomalpolysaccharide based Salmonella Shigella vaccineThe VesiVaxsystem will be formulated with promising mucosal immune response stimulating adjuvants and conjugated to Salmonella and Shigella polyssacahride antigensThe liposomes will be first evaluated in CDmice to determine if a scaffold protein is necessary for a strong immune responseThe optimized VesiVaxsystem will then be used to screen the promising mucosal stimulatingadjuvants in miceThe mice will be evaluated for lgG and lgA antibody levels in serumfecal matter and bronchoalveolar lavagesThe serum antibodies will also be assessed for binding to intact Salmonella and Shigella cells by flow cytometrySuccessful completion of this Phase I project will lead to candidate Salmonella Shigella formulation sfor scale upmanufacturing development in Phase II
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- Development of a VesiVax TLR7 Formula as an Effective Adjuvant
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense